Want to see FR:ALCLS full AI Analyst Report?
ALCLS Stock Chart & Stats
€2.59
<€0.01(0.23%)
At close: 4:00 PM EDT
€2.59
<€0.01(0.23%)
Day’s Range― - ―
52-Week Range€2.03 - €4.84
Previous CloseN/A
Volume109.61K
Average Volume (3M)852.48K
Market Cap
€178.50M
Enterprise Value€218.11
Total Cash (Recent Filing)€185.47M
Total Debt (Recent Filing)€82.33M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)€50.46M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins indicate the company's underlying product and service economics are strong: manufacturing, licensing and platform services capture high value per unit. As revenue scale improves, high gross margins support durable operating leverage and faster path to profitability once fixed R&D burdens stabilize.
Partner/licensing Revenue ModelA partner-funded business model provides non‑dilutive financing, validates technology through third‑party commitments, and creates milestone-linked cash inflections. This structure reduces sole commercialization risk for a clinical‑stage company and offers repeatable revenue streams that can persist through development into commercialization.
Improving Revenue ScaleMeaningful revenue growth versus prior troughs demonstrates improving commercial traction with collaborators and growing utilization of the platform. Durable top‑line expansion increases the chance to spread fixed development and manufacturing costs, enhancing future margin conversion and reducing reliance on external financing over time.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow indicate the company is burning cash to fund development and operations. Absent consistent partner upfronts or financings, ongoing burn undermines runway, forces periodic capital raises, dilutes shareholders, and constrains the ability to invest steadily in pivotal trials and scale manufacturing.
Rising Leverage, Shrinking EquityGrowing leverage and a declining equity base reduce financial flexibility and increase refinancing/interest risk. For a clinical‑stage biotech, tighter balance sheet capacity can limit negotiating power on partnerships, raise cost of capital, and elevate the chance of unfavorable financing terms during critical development milestones.
Deep Negative ProfitabilityVery large negative margins reflect that operating costs far exceed current revenue. Until the company converts development programs to higher recurring revenues or meaningfully cuts fixed costs, sustained losses will persist. This structural profitability gap increases reliance on external funding and makes long‑term value creation contingent on successful clinical outcomes or major partnerships.
Cellectis SA News
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €2.03 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €178.50M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -€0.153 earnings per share for the quarter, beating the consensus estimate of -€0.221 by €0.068.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.23.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.153 in its last earnings report, beating expectations of -€0.221. Following the earnings report the stock price went up 1.658%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
ALCLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all FR:ALCLS earnings summariesTechnical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―